Obeticholic Acid for Prevention in Barrett's Esophagus
Not yet recruiting
National Cancer Institute (NCI)
Phase 2
2021-12-08
This phase II trial studies the effect of obeticholic acid in treating patients with
Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to
neoplastic progression in Barrett's esophagus. Obeticholic acid, may help increase bile flow
from the liver while suppressing bile acid production, therefore reducing the exposure of the
liver to toxic levels of bile acids which is potentially linked to cancer development.
Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP)
Not yet recruiting
M.D. Anderson Cancer Center
Phase 1
2022-03-31
This is a trial that intends to evaluate the effect of treatment with the drug obeticholic
acid in the treatment of the Familial Adenomatous Polyposis condition.
Testing Obeticholic Acid for Familial Adenomatous Polyposis
Not yet recruiting
National Cancer Institute (NCI)
Phase 2
2022-07-11
This phase IIa trial investigates if giving obeticholic acid (OCA) has an effect on the
number of polyps in the small bowel and colon in patients with familial adenomatous polyposis
(FAP). FAP is a rare gene defect that increases the risk of developing cancer of the
intestines and colon. OCA is a drug similar to bile acids, a fluid made and released by the
liver. It binds to a receptor in the intestine that is believed to have a positive effect on
preventing cancer development. OCA has been effective in treating primary biliary cholangitis
(PBC), a liver disease, and is approved by the Food and Drug Administration (FDA). There have
been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet
known whether OCA works on reducing the number of polyps in patients with FAP.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
